<DOC>
	<DOCNO>NCT01761019</DOCNO>
	<brief_summary>Oral therapy psoriasis , include methotrexate acitretin , often less effective use monotherapy ( without oral medicine cream ) new biologic inject drug . However , oral medication also less expensive biologic agent may safer use patient . The purpose study determine add topical psoriasis medicine , calcipotriene/betamethasone topical suspension ( Taclonex topical suspension ) , improve severity psoriasis patient already methotrexate acitretin determine add topical suspension reduce desire patient switch biologic agent treat psoriasis .</brief_summary>
	<brief_title>A Study Determine Efficacy Taclonex Topical Suspension Supplement Non-biologic Systemic Therapy</brief_title>
	<detailed_description>Many patient mild psoriasis able control disease symptom topical medication alone . There variety topical option available , include corticosteroid , synthetic vitamin D3 , vitamin A , coal tar , salicylic acid number product vary efficacy . The combination topical suspension calcipotriene 0.005 % betamethasone dipropionate 0.064 % first-line treatment moderate severe psoriasis vulgaris FDA approve use skin scalp adult 18 year old . This treatment combine pharmacological effect calcipotriene hydrate synthetic vitamin D3 analog betamethasone dipropionate synthetic corticosteroid . It well tolerate low rate adverse event accord pool safety data 2700 patient use calcipotriene/betamethasone combination clinical trial . Calcipotriene/betamethasone topical suspension also show positive impact patient quality life , see clinical trial utilize patient report outcome Dermatology Life Quality Index ( DLQI ) Psoriasis Disability Index . Calcipotriene/betamethasone topical suspension therapy commonly use treat patient mild moderate psoriasis . Currently , formal trial study efficacy calcipotriene/betamethasone topical suspension use conjunction methotrexate acitretin . In order well understand effectiveness treatment combination , conduct preliminary , open label , single arm prospective study determine benefit add betamethasone-calcipotriene topical suspension ongoing systemic psoriasis therapy subject complete clearance psoriasis single systemic agent alone .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Subjects age 18 year older stable plaque psoriasis duration least 6 month . Subject must currently use stable dose , stable disease severity , single nonbiologic systemic psoriasis medication ( methotrexate acitretin ) least 2 month . Subject must plan continue current systemic agent , standard care monitor medication All lab require methotrexate acitretin do accord standard care . If woman , entry must : Postmenopausal , practice highly effective method birth control Women childbearing potential must negative urine pregnancy test prior randomization Subject must able willing provide write informed consent participate . Nonplaque psoriasis ( pustular , erythrodermic , guttate ) . Use exclude therapy : phototherapy use currently 4 week prior baseline , use 1 systemic therapy 2 month prior baseline , use topical steroid , tar preparation , vitamin D analog 4 week prior baseline . Subjects currently take take past 60 day , reason , medication , opinion investigator , suppress immune response . This may include limited systemic steroid , azathioprine , cyclosporine , FK506 , mycophenolate mofetil , mycophenolic acid , etanercept , adalimumab , infliximab , ustekinumab , cimzia , biologic agent target cell cytokine immune system . Subjects use time past Taclonex topical suspension Taclonex ointment Subjects pregnant , nursing , plan become pregnant course study . Presence unstable medical psychiatric condition , opinion investigator , could impair subject compliance . Subject active infection within 30 day prior baseline . Known suspect disorder calcium metabolism Known suspect severe kidney liver disease . Known suspected hypersensitivity component ( ) investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>Taclonex</keyword>
	<keyword>Acitretin</keyword>
	<keyword>Methotrexate</keyword>
</DOC>